Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 19/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768655 | 0.81 | EPHX2 (0.45) | EPHX2ALOX5HTTHDAC3HDAC1 | |
| SCHEMBL4014027 | 0.81 | EPHX2 (0.71) | EPHX2ALOX5HTTHDAC3HDAC1 | |
| SCHEMBL13768936 | 0.79 | EPHX2 (0.43) | EPHX2ALOX5HTTHDAC3HDAC1 | |
| SCHEMBL13768657 | 0.79 | EPHX2 (0.45) | EPHX2ALOX5HDAC3HDAC1HDAC7 | |
| SCHEMBL13768935 | 0.75 | EPHX2 (0.47) | EPHX2 | |
| SCHEMBL13768934 | 0.74 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL13772387 | 0.73 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL13768659 | 0.73 | EPHX2 (0.37) | EPHX2 | |
| SCHEMBL12931898 | 0.69 | EPHX2 (0.77) | EPHX2ALOX5HTTHDAC3HDAC1 | |
| SCHEMBL4014035 | 0.64 | EPHX2 (0.71) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |